Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Operating Expenses: 2017-2025

Historic Operating Expenses for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $88.6 million.

  • Cidara Therapeutics' Operating Expenses rose 409.53% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 45.16%. This contributed to the annual value of $177.4 million for FY2024, which is 252.34% up from last year.
  • Per Cidara Therapeutics' latest filing, its Operating Expenses stood at $88.6 million for Q3 2025, which was up 223.65% from $27.4 million recorded in Q2 2025.
  • Cidara Therapeutics' Operating Expenses' 5-year high stood at $96.3 million during Q2 2024, with a 5-year trough of -$64.1 million in Q4 2021.
  • Over the past 3 years, Cidara Therapeutics' median Operating Expenses value was $23.3 million (recorded in 2023), while the average stood at $34.5 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Operating Expenses slumped by 353.72% in 2021, and later spiked by 713.36% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Operating Expenses (Quarterly) stood at -$64.1 million in 2021, then surged by 136.96% to $23.7 million in 2022, then plummeted by 51.67% to $11.5 million in 2023, then soared by 372.92% to $54.2 million in 2024, then skyrocketed by 409.53% to $88.6 million in 2025.
  • Its Operating Expenses was $88.6 million in Q3 2025, compared to $27.4 million in Q2 2025 and $25.3 million in Q1 2025.